US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.98 against a street estimate of 0.89 — a beat of 10.1%.
Analysts rate Prestige Brand Holdings Inc a buy (5 buy, 2 hold, 0 sell out of 7) with an average price target of $67.80.
CONFIDENT Prestige delivered a strong Q1, raised revenue, EPS and cash-flow guidance through acquisitions, while Clear Eyes supply recovery remains a multiyear execution risk. Q1 FY27 No geographic regions beyond North America and International were discussed. Analysts focused on acquisition accretion, margins, retailer timing, Clear Eyes recovery and integration capacity. Management emphasized strong underlying consumption, temporary timing effects and a multiyear supply recovery. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 16.53% |
| Ariel Investments, LLC | 10.28% |
| Vanguard Portfolio Management, LLC | 5.96% |
| Dimensional Fund Advisors, Inc. | 5.62% |
| Fuller & Thaler Asset Management Inc | 4.92% |
| Vanguard Capital Management, LLC | 4.51% |
| State Street Corp | 4.47% |
| Brandes Investment Partners & Co | 4.33% |
| Document | Date |
|---|---|
| Board / officer change · Q2 FY2027 PRESTIGE CONSUMER HEALTHCARE INC. (PBH) - FORM 8-K SUMMARY Filing Date: August 10, 2026 --- OTHER NOTABLE POINTS • Jeffrey Zerillo, Senior Vice Pre | 2026-08-14 |
| Quarterly report · Q1 FY2027 PRESTIGE CONSUMER HEALTHCARE INC. - Q1 FY2027 (ENDED JUNE 30, 2026) SUMMARY HEADLINE NUMBERS • Total Revenues: $265.7 million (Q1 2026) vs. $249.5 m | 2026-08-06 |
| Results announced · Q2 FY2027 PRESTIGE CONSUMER HEALTHCARE INC. - Q1 FY2027 EARNINGS SUMMARY HEADLINE NUMBERS • Q1 FY2027 revenue of $265.7 million, up 6.5% year-over-year from $ | 2026-08-06 |
| Material agreement · Q2 FY2027 PRESTIGE CONSUMER HEALTHCARE INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company issued $400.0 million in senior notes on July 15, 2026 • Notes carry | 2026-07-15 |
| Material agreement · Q1 FY2027 PRESTIGE CONSUMER HEALTHCARE INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company borrowed $95,000,000 under amended Term Loan Credit Agreement on Jul | 2026-07-06 |
| Proxy statement · Q1 FY2027 PRESTIGE CONSUMER HEALTHCARE INC. - PROXY STATEMENT SUMMARY --- HEADLINE NUMBERS • Revenue of $1,089M in fiscal 2026 • Adjusted Diluted EPS of $4.3 | 2026-06-29 |
| Annual report FY2026 PRESTIGE CONSUMER HEALTHCARE INC. - FISCAL YEAR 2026 SUMMARY HEADLINE NUMBERS • Fiscal year ended March 31, 2026 • Market capitalization: $2,970.2 m | 2026-05-14 |
| Quarterly report · Q3 FY2026 PRESTIGE CONSUMER HEALTHCARE INC. – QUARTERLY SUMMARY (Q3 FY2026) HEADLINE NUMBERS • Net Sales (9 months): $806.1 million vs. $840.4 million prior y | 2026-02-05 |
Readable in the app.
| Announcement | Date |
|---|---|
| Acquisition of LaCorium Health Australia and related entities completed Prestige Consumer Healthcare completed its acquisition of LaCorium Health (an Australian company) on July 1, 2026. To finance this deal, the company borrowed $95 million under an amended ter | 2026-07-06 |
| Term loan facility arranged to finance acquisition transactions Prestige Consumer Healthcare borrowed $1.045 billion through a new term loan on June 12, 2026, to finance unspecified transactions that closed that day. The company also secured an additiona | 2026-06-16 |
| Acquisition of Australian therapeutic skin care company for approximately $150 million Prestige Consumer Healthcare Inc. announced it will acquire five Australian skincare companies (including LaCorium Health Australia and Laderma Holdings) for approximately $150 million in ca | 2026-05-13 |
| Definitive agreement to acquire over-the-counter consumer health products portfolio Prestige Consumer Healthcare Inc. announced on March 19, 2026 that its subsidiary will acquire a portfolio of over-the-counter consumer health products from Foundation Consumer Brands for $1 | 2026-03-20 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Prestige Brand Holdings Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.